188 results on '"Spierings J"'
Search Results
2. Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3intCD161 + RORγt + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies
3. How to Assess a Patient for HSCT
4. AB1176 SCOPING REVIEW TO GUIDE THE DEVELOPMENT OF AN ARTICULAR SCORE IN SYSTEMIC SCLEROSIS (ASSESS SCORE)
5. AB1142 DERMAL CELLULAR SENESCENCE AND ENDOTHELIAL-TO-MESENCHYMAL TRANSITION IN PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH CYCLOPHOSPHAMIDE OR AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION
6. AB1679-PARE THE IMPACT OF HAND FUNCTION IMPAIRMENT ON DAILY LIFE IN DUTCH PATIENTS WITH SYSTEMIC SCLEROSIS - A QUALITATIVE STUDY
7. POS0823 MULTI-CENTRE VALIDATION OF THE PASTUL QUESTIONNAIRE FOR SELF-ASSESSMENT OF SKIN SEVERITY IN SYSTEMIC SCLEROSIS
8. Vroege herkenning van progressieve diffuse cutane systemische sclerose is essentieel voor optimale behandeling: Houd het strak in de gaten!
9. How to Assess a Patient for HSCT
10. POS0637 USING THE “POTENTIAL-OUTCOMES FRAMEWORK” TO PREDICT ADDED VALUE OF MORE INTENSIVE INITIAL THERAPY FOR INDIVIDUAL EARLY RA PATIENTS
11. AB0857 ANTI-THYMOCYTE GLOBULIN EXPOSURE IS ASSOCIATED WITH TREATMENT RESPONSE IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS UNDERGOING AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION
12. POS0953 PROGRESSIVE PULMONARY FIBROSIS IN CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASES
13. POS0886 18F-FDG PET-CT OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH EARLY SYSTEMIC SCLEROSIS
14. OP0026 INCREASED VASCULAR INFLAMMATION ON PET-CT IN PSORIATIC ARTHRITIS PATIENTS IN COMPARISON WITH HEALTHY CONTROLS
15. Physical Therapy in Systemic Sclerosis: The Patient Perspective.
16. Antenatal ureaplasma infection impairs development of the fetal ovine gut in an IL-1-dependent manner
17. Positron Emission Tomography to Improve Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation
18. POS0469 ENDOTHELIAL TO MESENCHYMAL TRANSITION AND SENESCENCE ARE PART OF THE FIBROTIC PATHOGENESIS IN SYSTEMIC SCLEROSIS
19. Unravelling the complexity of psoriatic arthritis on a journey towards precision medicine
20. Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis
21. Physical therapy in patients with systemic sclerosis: physical therapists' perspectives on current delivery and educational needs
22. Physical therapy in patients with systemic sclerosis: physical therapists’ perspectives on current delivery and educational needs
23. Lifelong learning : how to past the test.
24. Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3intCD161 + RORγt + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies.
25. Opening the black box of non-pharmacological care in systemic sclerosis
26. Physical therapy in patients with systemic sclerosis: physical therapists’ perspectives on current delivery and educational needs
27. AB0914-PARE INFORMATION PREFERENCES ABOUT TREATMENT OPTIONS IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A DELPHI CONSENSUS STUDY
28. POS0249 THE EFFECT OF NASAL STAPHYLOCOCCUS AUREUS COLONIZATION ON DISEASE ACTIVITY AND THE EFFECT OF ANTIBIOTIC TREATMENT IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS; A RETROSPECTIVE COHORT STUDY
29. AB0402 SELF-ASSESSMENT OF SCLERODERMA SKIN THICKNESS: DEVELOPMENT AND VALIDATION OF THE PASTUL QUESTIONNAIRE
30. AB0812 BIOMARKERS FOR CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE: A PILOT STUDY
31. AB0387 SYSTEMIC AND LOCAL THERAPIES FOR EAR, NOSE AND THROAT MANIFESTATIONS IN ANCA-ASSOCIATED VASCULITIS: A SYSTEMATIC REVIEW
32. AB0884-HPR PERSONALISED TREATMENT GOALS IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASE
33. POS1419 PREDICTIVE FACTORS FOR PULMONARY PROGRESSION IN PATIENTS WITH CONNECTIVE TISSUE DISEASE AND INTERSTITIAL LUNG DISEASE
34. Physical therapy in patients with systemic sclerosis: physical therapists' perspectives on current delivery and educational needs.
35. Requirements for systemic sclerosis expert centres in the Netherlands
36. How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?
37. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol
38. BIOMARKERS FOR CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE: A PILOT STUDY
39. PERSONALISED TREATMENT GOALS IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASE
40. PREDICTIVE FACTORS FOR PULMONARY PROGRESSION IN PATIENTS WITH CONNECTIVE TISSUE DISEASE AND INTERSTITIAL LUNG DISEASE
41. Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all
42. Lifelong learning : odyssey or holy grail.
43. Re-evaluating inclusion criteria for autologous hematopoietic stem cell transplantation in advanced systemic sclerosis: Three successful cases and review of the literature
44. Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all
45. The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation
46. Diagnosing and treating antiphospholipid synarome: a consensus paper
47. Election '07 : it's crunch time for Australia's skilling effort.
48. Living with systemic sclerosis: exploring its impact on caregivers
49. Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient's perspective
50. Room for improvement in non-pharmacological systemic sclerosis care? - a cross-sectional online survey of 650 patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.